Core Insights - Qianjin Pharmaceutical's stock price increased by 2.01% on November 25, reaching 10.66 CNY per share, with a market capitalization of 5.247 billion CNY [1] - The company reported a revenue of 2.718 billion CNY for the first nine months of 2025, showing a year-on-year growth of 0.14%, and a net profit of 187 million CNY, up 11.47% year-on-year [2] - The company has distributed a total of 2.375 billion CNY in dividends since its A-share listing, with 449 million CNY distributed in the last three years [3] Company Overview - Qianjin Pharmaceutical, established on August 13, 1993, and listed on March 12, 2004, is located in Zhuzhou, Hunan Province [1] - The company's main business includes the research, production, and sales of traditional Chinese medicine, chemical drugs, and women's hygiene products, with revenue contributions of 39.95% from drug wholesale and retail, 28.33% from traditional Chinese medicine production, and 28.28% from Western medicine production [1] Shareholder and Market Activity - As of September 30, 2025, the number of shareholders decreased by 9.85% to 36,800, while the average circulating shares per person increased by 10.92% to 11,360 shares [2] - Major new institutional shareholders include Invesco Great Wall CSI Dividend Low Volatility 100 ETF and Tianhong CSI Dividend Low Volatility 100 ETF, among others [3]

Group 1 - The company held a Q3 2025 performance briefing on November 20, 2025, to discuss operational results and financial status with investors [1] - The meeting featured participation from the chairman, independent director, board secretary, and financial officer, who addressed investor inquiries [1] Group 2 - The company is expanding its production capacity through new workshops and upgrading existing production lines to meet the demand for new products [2] - The company reported a 32% year-on-year revenue growth in its sanitary products business for Q3 2025, while also focusing on digital transformation and new retail strategies [2] - The company maintains a leading position in the gynecological traditional Chinese medicine market, with a market share of 25.8% for its main product in 2024 [2] Group 3 - The company’s investment in Hunan Newhe Biopharmaceutical Co., Ltd. aims to enhance resource integration and strategic layout within the pharmaceutical industry [4] - The company is currently in the process of integrating three pharmaceutical companies to improve overall synergy [4] - The company’s cash management yields approximately 2% annually [8] Group 4 - The company plans to maintain stable dividends, having consistently provided a high proportion of cash dividends since its listing [6] - The company’s acquisition of Qianjin Xiangjiang and Qianjin Xieli is expected to enhance its performance, with consolidation of financial results starting in October and November 2025 [5] Group 5 - The company is undergoing a digital transformation in its pharmacy operations, shifting from a product-centric to a customer-centric model [9] - The collaboration with Alibaba focuses on building a C-end operation platform and a smart women's health platform [10]

证券代码：600479 证券简称：千金药业 公告编号：2025-059 问题 2：1、注意到本年三季度虽然利润比去年有增长，但相比 株洲千金药业股份有限公司 关于 2025 年第三季度业绩说明会召开情况的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 株洲千金药业股份有限公司（以下简称"公司"）于 2025 年 11 月 20 日在价值在线（www.ir-online.cn）召开了公司 2025 年第三季 度业绩说明会。本次业绩说明会以网络互动方式召开，公司针对报告 期内经营成果、财务状况与投资者进行互动交流和沟通，在信息披露 允许的范围内就投资者普遍关注的问题进行回答。现将相关情况公告 如下： 一、 业绩说明会召开情况 本次业绩说明会于 2025 年 11 月 20 日（星期四） 15:00-16:00 以网络互动的形式在价值在线（www.ir-online.cn）召开，公司董事 长蹇顺，独立董事马理，董事会秘书朱溧，副总经理兼财务负责人彭 意花参加了本次说明会并就投资者关注的问题进行了回答。 二、本次说明会投资 ...

Group 1 - The core focus of the article is on the development of a modern industrial system in China during the "14th Five-Year Plan" period, emphasizing the integration of technological and industrial innovation to strengthen the real economy [9][10][12] - The article highlights the importance of traditional industries, such as steel and pharmaceuticals, in driving economic growth and their ongoing transformation through digitalization and automation [12][13][14] - The article mentions that since 2016, companies like Hunan Huazhong Steel have been implementing smart manufacturing solutions, resulting in significant efficiency improvements, such as reducing the steel slab rotation time from 6.7 seconds to 3.93 seconds [12][13] Group 2 - The article discusses the emergence of new and future industries, particularly in sectors like renewable energy, aerospace, and low-altitude economy, as part of the strategic focus for the "14th Five-Year Plan" [15][16] - Companies like Hidi Intelligent Driving Technology are capitalizing on market demands for automation in hazardous environments, such as mining, with significant policy support driving growth in this sector [16][18] - The article notes that the humanoid robot market in China is expected to reach approximately 870 billion yuan by 2030, indicating rapid growth in the robotics sector [17] Group 3 - The article emphasizes the need for collaborative innovation among government, enterprises, and research institutions to create a conducive environment for the development of a modern industrial system [19][20] - It highlights the establishment of over 230 excellent smart factories and 1,260 5G factories in China since the beginning of the "14th Five-Year Plan," showcasing the country's commitment to advancing its manufacturing capabilities [13][19] - The article points out that the value added by the "new economy" is projected to exceed 18% of GDP by 2024, indicating a significant shift towards new industries and business models [18][22]

Group 1 - The second extraordinary general meeting of shareholders was held on November 17, 2025, at the company's headquarters in Zhuzhou [2][3] - All resolutions presented at the meeting were approved without any objections [2] - The meeting was convened in accordance with the Company Law and the company's articles of association, with the chairman presiding over the session [2][3] Group 2 - All eight current directors attended the meeting, with independent directors participating via telecommunication [3] - A special resolution to cancel the supervisory board, change the registered capital, and amend the articles of association was passed with over two-thirds of the voting rights [3][4] - The meeting was witnessed by lawyers from Hunan Qiyuan Law Firm, confirming the legality of the meeting's procedures and resolutions [4]

湖南启元律师事务所 关于 株洲千金药业股份有限公司 2025年第二次临时股东大会的 法律意见书 致：株洲千金药业股份有限公司 湖南启元律师事务所（以下简称"本所"）接受株洲千金药业股份有限公司 （以下简称"公司"）的委托，指派本律师出席了公司 2025 年第二次临时股东大 会（以下简称"本次股东大会"），对本次股东大会的召集和召开程序、出席会 议人员及召集人的资格、表决程序和表决结果的合法有效性进行现场律师见证， 并发表本法律意见。 本律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中 华人民共和国证券法》（以下简称"《证券法》"）、《上市公司股东会规则》 （以下简称"《股东会规则》"）等我国现行法律、法规、规范性文件以及《株 洲千金药业股份有限公司章程》（以下简称"《公司章程》"）的有关规定出具 本法律意见书。 本律师声明如下： （一）本律师根据本法律意见书出具日以前已经发生或者存在的事实，严格 履行了法定职责，遵循了勤勉尽责和诚实信用原则，进行了充分的核查验证，保 证本法律意见所认定的事实真实、准确、完整，所发表的结论性意见合法、准确， 不存在虚假记载、误导性陈述或者重大遗漏，并承担相应法律 ...

证券代码：600479 证券简称：千金药业 公告编号：2025-058 株洲千金药业股份有限公司 2025年第二次临时股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 本次会议由公司董事会召集，会议由公司董事长蹇顺主持。会议的召集、召 (一)股东大会召开的时间：2025 年 11 月 17 日 (二)股东大会召开的地点：株洲市天元区株洲大道 801 号千金药业三楼第二会议 室 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 249 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 181,104,192 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | 份总数的比例（%） | 36.7940 | (四)表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 开符合《公司法》及《公司章程》的规定。 (五)公司董事 ...

Core Viewpoint - The company, Zhuzhou Qianjin Pharmaceutical Co., Ltd., is set to hold a performance briefing for the third quarter of 2025 on November 20, 2025, to provide insights into its operational results and financial status [3][6]. Group 1: Meeting Details - The performance briefing will take place on November 20, 2025, from 15:00 to 16:00 [2][6]. - The meeting will be conducted in an interactive online format via the website www.ir-online.cn [2][4]. - Investors can submit questions prior to the meeting through a designated link or by scanning a QR code [5][6]. Group 2: Participants - Key participants in the meeting will include the Chairman, Mr. Jian Shun, the Board Secretary, Ms. Zhu Li, the Financial Officer, Ms. Peng Yihua, and the Independent Director, Mr. Ma Li [4]. Group 3: Contact Information - For inquiries, investors can contact Ms. Liu at phone number 0731-22496088 or via email at qjyydb@qjyy.com [7].

证券代码：600479 证券简称：千金药业 公告编号：2025-057 株洲千金药业股份有限公司 关于召开 2025 年第三季度业绩说明会的公告 https://eseb.cn/1t8AbrYsquk或使用微信扫描小程序码进行会前提 问，公司将通过本次业绩说明会，在信息披露允许范围内就投资者普 遍关注的问题进行回答。 一、 说明会类型 株洲千金药业股份有限公司（以下简称"公司"）已于 2025 年 10 月 30 日发布公司 2025 年第三季度报告，为便于广大投资者更全 面深入地了解公司经营成果、财务状况，公司计划于 2025 年 11 月 20 日 15:00-16:00 举行 2025 年第三季度业绩说明会，就投资者关心 的问题进行交流，广泛听取投资者的意见和建议。 二、 说明会召开的时间、地点 会议召开时间：2025 年 11 月 20 日(星期四) 15:00-16:00 会议召开地点：价值在线（www.ir-online.cn） 会议召开方式：网络互动方式 会议问题征集：投资者可于 2025 年 11 月 20 日前访问网址 （一）会议召开时间：2025 年 11 月 20 日（星期四）15:00 ...

Group 1: Economic Overview - In 2024, the industrial and manufacturing sectors in Zhuzhou are projected to account for 39.9% and 37.4% of GDP, respectively, marking increases of 0.9 and 1.2 percentage points since 2020, leading the province of Hunan [1] - Zhuzhou is recognized as a significant industrial base, having been one of the eight major industrial cities established during the early years of New China, contributing to various industrial milestones [1] Group 2: Advanced Manufacturing Development - Zhuzhou has developed three national advanced manufacturing clusters in rail transit equipment, small aircraft engines, and ultra-high voltage transmission equipment, along with three national characteristic industry clusters for small and medium enterprises [1] - The city has improved its ranking in the national advanced manufacturing cities from outside the top 50 in 2020 to 37th in 2024 [1] Group 3: Digital Transformation and Innovation - Zhuzhou has established the world's first intelligent manufacturing workshop for bogies and the first 5G automatic detection production line for ceramics in China, with digitalization coverage in large-scale manufacturing enterprises reaching 81% [2] - Zhuzhou's major enterprise, CRRC Zhuzhou Electric Locomotive Co., has implemented several intelligent production lines, enhancing manufacturing capabilities [2] Group 4: Pharmaceutical Industry Advancements - Zhuzhou Qianjin Pharmaceutical Co., a government-controlled listed company, has made significant strides in digital transformation, reducing average R&D costs from 12.468 million to 5.867 million yuan and cutting approval times for product registration from 8 years to under 3 years [5] - The company has also improved production efficiency, reducing monthly production scheduling time from over 3 days to under 30 minutes, and increasing output by 33% [5] Group 5: Future Industry Focus - The city aims to accelerate the development of world-class industrial clusters in rail transit and small aircraft engines by 2025, while also promoting advanced materials and semiconductor industries [8] - Zhuzhou is focusing on emerging industries, particularly in "bottleneck" areas, to support technological advancements and the development of strategic emerging industry clusters [8] Group 6: Government Support and Infrastructure - The local government has implemented a supportive environment for the North Star industry, with a comprehensive development plan and policies to facilitate business operations [9] - The establishment of a satellite manufacturing factory in Zhuzhou has been expedited due to favorable government policies and support, enhancing the city's industrial capabilities [9] Group 7: Manufacturing Growth Metrics - From January to September this year, Zhuzhou's manufacturing output value increased by 10.4% year-on-year, with 27 out of 37 industrial categories showing positive growth [12] - Key industrial clusters such as metal products and electrical machinery have demonstrated significant growth rates of 36.8% and 30.8%, respectively [12]